Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

GlaxoSmithKline (GSK) has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to aid the development of a vaccine against the new coronavirus, 2019-nCoV.

Meanwhile, the Government of UK has committed £20m to develop vaccines for the coronavirus, as well as other infectious diseases.

The number of deaths and infection cases due to the Wuhan coronavirus continues to rise. As of the end of 2 February, the death toll reached 362 and confirmed cases were 17,386.

GSK and CEPI partnership

As part of its alliance with the CEPI, GSK will provide access to its pandemic vaccine adjuvant platform technology to help speed-up the development of coronavirus vaccine candidates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Certain vaccines consist of an adjuvant to boost the immune response against infections.

In a pandemic, an adjuvant can be useful as it can decrease the amount of antigen per dose, enabling the manufacture of more vaccine doses, noted GSK.

GSK Vaccines chief medical officer Thomas Breuer said:Our adjuvant technology has previously been used successfully in the pandemic flu setting. It enables using only small quantities of the vaccine antigen which allows the production of more doses of the vaccine – a crucial advantage in a pandemic.”

The coalition will manage any arrangements between any CEPI-funded entities who want to test their vaccine platform with GSK’s adjuvant technology to create coronavirus vaccines.

The University of Queensland in Australia signed the first deal for GSK’s technology.

In addition to the University of Queensland, CEPI is funding 2019-nCoV vaccine programmes by CureVac, Inovio Pharmaceuticals and Moderna, which is working with the US National Institute of Allergy and Infectious Diseases.

UK funding for coronavirus vaccine

The £20m funding will also be used to support the development of diagnostics and cures to address the threat of viruses in the future. The UK is providing these funds to CEPI.

Funding will be used for three coronavirus vaccine development programmes to advance candidates into clinical testing.

UK Health Secretary Matt Hancock said: “The £20m announced today will help our globally recognised vaccine development capabilities continue to develop new defences against emerging diseases including coronavirus.”

Originally, CEPI formed to address the Ebola epidemic in West Africa.